** Shares of drugmaker Alkermes ALKS.O rise 6.38% to $34
** Co posts Q4 sales of $430 million, beating analysts' estimate of $379 million - LSEG
** Sees 2025 revenue between $1.3 billion and $1.4 billion vs est $1.4 billion
** Expects mid-stage study data of neurological disorder drug in H2 2025
** Plans to begin early-stage study of drugs to treat sleep disorders
** In the last 12 months, ALKS rose 7.6%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.